The Press Release Resource

• Tweet

• Tweet

The original Nano Med Tech contingent consisted of an elite team of eleven Chinese Nationals, all of whom obtained doctorates in the nanotechnology field at top-tier US and UK universities. Since establishing themselves as a viable and marketable entity, the star of Nano Med Tech has seemingly maximized upon its’ smooth, upward trajectory. IPO gurus are approaching weariness in their lauding of this revolutionary nanotech-medical treatment which is currently under the scrutiny of a widely publicized FDA approval matrix. Additionally, the firms innovative technologies are said to be attracting the attentions of the pharma sector bellweathers as approval progresses.
Whilst the approval status and indeed, the precise nature of the patent are shrouded in secrecy, concrete support for market approval of this blossoming ‘IPO-to-be’ has recently been provided in the form of news that they have been granted expansive funding to include a hand-picked US-based group of headline-name doctorates for the purpose of steam-lining the regulatory process.
The latest arm of Nano Med Tech is understood to be benefitting from access to highly-funded university facilities across North America. A spokesperson from Nano Med Tech revealed “We can confirm that Nano Med Tech have engaged the services of a further six researchers based in the US who are focused on facilitating delivery of the ongoing FDA requirements”.
The spokesperson could not elaborate on the specifics; likely due to their rigid non-disclosure predicament with the elusive US-based financiers. The, as-yet, unidentified VC entity are widely believed to be providing funds to the universities at which the new Nano Med Tech channel are based, in exchange for the continued use of state-of-the-art research facilities.
Whilst relatively benign in its nature, the news has prompted comments from certain corners of the investment community which monitor the field, that Nano Med Tech are making better than expected progress with the approvals process, given their decision to provide an in-country US presence, and the apparent justification on the part of the, as yet, unidentified VC, to expand funding to finance the new personnel.
One emerging markets analyst monitoring the Nano Med Tech situation commented that “FDA gateway approval can be a lengthy and drawn out process” which, in cases where the argument for full approval is strong, but involves cases for which there is no precedent “can be facilitated through day-to-day dialogue between the applicants and the regulators to ensure fulfillment of this type of blue-sky requirement.”